{"id":"NCT01515189","sponsor":"Bristol-Myers Squibb","briefTitle":"Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab","officialTitle":"A Randomized Double-Blind Phase III Study of Ipilimumab Administered at 3 mg/kg Versus at 10 mg /kg in Subjects With Previously Treated or Untreated Unresectable or Metastatic Melanoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-02-17","primaryCompletion":"2016-02-06","completion":"2017-08-17","firstPosted":"2012-01-24","resultsPosted":"2017-03-24","lastUpdate":"2019-07-31"},"enrollment":831,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Melanoma"],"interventions":[{"type":"BIOLOGICAL","name":"Ipilimumab","otherNames":["Yervoy","BMS-734016"]}],"arms":[{"label":"Arm 1: Ipilimumab (3 mg/kg)","type":"EXPERIMENTAL"},{"label":"Arm 2: Ipilimumab (10 mg/kg)","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine whether giving Ipilimumab at a dose of 10mg/kg will extend the lives of subjects with unresectable or metastatic melanoma more than giving Ipilimumab at a dose of 3 mg/kg","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"Approximately 48 months (assessed up to February 2016)","effectByArm":[{"arm":"Ipilimumab (10 mg/kg)","deltaMin":15.7,"sd":null},{"arm":"Ipilimumab (3 mg/kg)","deltaMin":11.53,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0400"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":88,"countries":["United States","Argentina","Australia","Austria","Belgium","Canada","Czechia","Denmark","France","Germany","Hungary","Israel","Italy","Mexico","Netherlands","Norway","Poland","South Africa","Spain","Sweden","Switzerland","United Kingdom"]},"refs":{"pmids":["32503946","31334596","28359784"],"seeAlso":["http://bms.com/studyconnect/Pages/home.aspx","http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx"]},"adverseEventsSummary":{"seriousAny":{"events":245,"n":364},"commonTop":["Diarrhoea","Pruritus","Fatigue","Rash","Nausea"]}}